In Vitro Virology
In Vitro Virology
批准号:
7418075
负责人:
Robert Walter Buckheit
金额:
$10.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-27 至 2013-05-31
关键词:
AlgorithmsAnti-Infective AgentsAntiviral AgentsBiochemicalBiologicalBiological AssayCell LineCellsCervicalChemistryClassClinicalComplexDataDendritic CellsDevelopmentEvaluationGelGenerationsGeographic LocationsGoalsGrowthHIVHIV drug resistanceIn VitroInflammatoryLaboratoriesLactobacillusLeadLiquid substanceMeasurementMeasuresModelingMulti-Drug ResistanceOligonucleotidesPreclinical TestingPropertyRangeReagentResearch Project GrantsResistanceScreening procedureSeminal PlasmaSeminal fluidStandards of Weights and MeasuresSupport of ResearchTestingTissuesToxic effectToxicity TestsToxicologyVaginaViralVirusVirus Replicationbasecell typedesigndrug resistant virusefficacy evaluationinhibitor/antagonistmacromoleculemacrophagemicrobicidemonocytepre-clinicalpreventprogramsresearch clinical testingresponsetransmission processvaginal fluidvirology
中文摘要
核心C:病毒学将支持研究项目一、二和三以及核心B和D,办法是提供
特定试剂,抗病毒和其他抗感染评估,以及嘧啶二酮类药物的疗效数据,
ISIS 5320寡核苷酸,以及NCp7病毒灭活剂单独和组合产品。核心C将
通过实施以下目标来实现这些目标:
目标1:初步抗病毒疗效和毒性测试:抗病毒疗效和毒性数据将用于
全病毒复制试验和特异性细胞和生化试验,以衡量其抗病毒作用
基于其定义的作用机理的活性杀菌剂和配方产品。毒性
每项抗病毒措施的评估将同时进行。目标2:评估
复配杀菌剂产品的活性:本目标的目的是利用体外标准品
杀微生物剂效力分析,以评估、量化和优先选择将被
作为长效杀菌剂开发用于在体外宫颈移植模型中的评估以及进一步的
作为凝胶和环状产品的开发。目的3:评估阴道液和精液的效果
关于病毒感染性和杀微生物剂的效力和毒性:我们将进行体外效力和毒性
使用精浆和阴道液添加剂对所进行的每一种抗病毒检测进行评估
进一步确定这些液体对病毒感染性、杀微生物剂作用和细胞的生物学特性
毒力。目标4:抗杀微生物剂病毒株的培育和对其能力的评估。
抑制野生型和抗药性病毒传播的杀微生物剂:我们将选择符合以下条件的病毒
对每种杀菌剂单独和联合使用的抗性,并评估其能力
完全抑制野生型和抗药性病毒传播的杀微生物剂。目的5:毒性
杀微生物剂产品和配方材料的评价:基于细胞的体外毒理学测试将是
利用细胞系、相关的乳杆菌种类和体外组织进行。目标6:临床前
单独和联合开发杀微生物剂产品:《标准》规定的铅杀菌剂产品
研究将根据临床测试的进展情况对其抗病毒潜力进行评估。
英文摘要
Core C: Virology will support Research Projects I, II and III and Cores B and D through the provision of
specific reagents, antiviral and other anti-infective evaluations, and efficacy data for the pyrimidinediones,
ISIS 5320 oligonucleotide, and NCp7 viral inactivating agents alone and in combination products. Core C will
accomplish these goals by implementation of the following objectives:
Objective 1: Primary Antiviral Efficacy and Toxicity Testing: The antiviral efficacy and toxicity data will utilize
whole virus replication assays and specific cellular and biochemical assays to measure the antiviral effects of
the active microbicide and formulated product based on their defined mechanisms of action. Toxicity
evaluations will be performed in parallel for each antiviral measurement. Objective 2: Evaluation of the
Activity of Combination Microbicide Products: The aim of this objective is to utilize standard in vitro
microbicide efficacy assays to evaluate, quantify and prioritize combinations of microbicide products to be
developed as long-lasting microbicides for evaluation in ex vivo cervical explant models as well as for further
development as gel and ring products. Objective 3: Evaluation of the Effects of Vaginal and Seminal Fluids
on Viral Infectivity and Microbicide Efficacy and Toxicity: We will perform in vitro efficacy and toxicity
evaluations using seminal plasma and vaginal fluid additives to each of the antiviral assays performed and to
further define the biological properties of these fluids on viral infectivity, microbicide action, and cellular
toxicity.Objective 4: Development of Microbicide-Resistant Virus Strains and Evaluation of the Ability of the
Microbicides to Inhibit the Transmission of Wild Type and Resistant Virus: We will select for viruses that are
resistant to each of the microbicides alone and in combination with one another and evaluate the ability of
the microbicides to totally suppress the transmission of wild type and resistant viruses.Objective 5: Toxicity
Evaluation of Microbicide Products and Formulated Materials: Cell-based in vitro toxicology testing will be
performed utilizing cell lines, relevant Lactobacilli species, and ex vivo tissues. Objective 6: Preclinical
Development of Microbicide Products Alone and In Combination: Lead microbicide products defined by the
studies will be assessed for their antiviral potential consistent with their advancement to clinical testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Critical Path IND-enabling Studies, Regulatory, and Product Development
-
批准号:8405106
-
项目类别:
-
资助金额:$94.2万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Determination of Dosing Concentrations of Formulated APIs using the MTSA
-
批准号:8404125
-
项目类别:
-
资助金额:$33.75万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Development and Evaluation of Dual Compartment Combination Microbicides
-
批准号:8699496
-
项目类别:
-
资助金额:$287.64万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Development and Evaluation of Dual Compartment Combination Microbicides
-
批准号:8862358
-
项目类别:
-
资助金额:$244.32万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Administrative
-
批准号:8405107
-
项目类别:
-
资助金额:$9.54万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Development and Evaluation of Dual Compartment Combination Microbicides
-
批准号:8374028
-
项目类别:
-
资助金额:$322.4万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Development and Evaluation of Dual Compartment Combination Microbicides
-
批准号:8494567
-
项目类别:
-
资助金额:$357.41万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Development and Evaluation of Dual Compartment Combination Microbicides
-
批准号:9060880
-
项目类别:
-
资助金额:$214.91万
-
财政年份:2012
-
负责人:Robert Walter Buckheit
-
依托单位:
Advanced Preclinical and Clinical Development and Regulatory Evaluations
-
批准号:8132428
-
项目类别:
-
资助金额:$87.07万
-
财政年份:2010
-
负责人:Robert Walter Buckheit
-
依托单位:
Discovery of drugs for use in the treatment and prevention of HIV infection using
-
批准号:7932473
-
项目类别:
-
资助金额:$26.83万
-
财政年份:2010
-
负责人:Robert Walter Buckheit
-
依托单位:
Development of Antimicrobial Peptides as Topical Microbicides
-
批准号:8092553
-
项目类别:
-
资助金额:$19.51万
-
财政年份:2010
-
负责人:Robert Walter Buckheit
-
依托单位:
Development of Antimicrobial Peptides as Topical Microbicides
-
批准号:7893461
-
项目类别:
-
资助金额:$20.04万
-
财政年份:2010
-
负责人:Robert Walter Buckheit
-
依托单位:
Discovery of drugs for use in the treatment and prevention of HIV infection using
-
批准号:8245298
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2010
-
负责人:Robert Walter Buckheit
-
依托单位:
Development of a Novel Semen-Activated Prodrug as an Anti-HIV Microbicide
-
批准号:7927021
-
项目类别:
-
资助金额:$20.46万
-
财政年份:2009
-
负责人:Robert Walter Buckheit
-
依托单位:
Advanced Preclinical and Clinical Development and Regulatory Evaluations
-
批准号:7681967
-
项目类别:
-
资助金额:$41.68万
-
财政年份:2009
-
负责人:Robert Walter Buckheit
-
依托单位:
Development of a Novel Semen-Activated Prodrug as an Anti-HIV Microbicide
-
批准号:7665990
-
项目类别:
-
资助金额:$18.62万
-
财政年份:2009
-
负责人:Robert Walter Buckheit
-
依托单位:
Development of Pyrimidinedione NNRTIs With a High Genetic Barrier to Resistance
-
批准号:7756022
-
项目类别:
-
资助金额:$23.11万
-
财政年份:2009
-
负责人:Robert Walter Buckheit
-
依托单位:
Mechanism of Action of Novel Dual Acting Pyrimidinediones
-
批准号:8012622
-
项目类别:
-
资助金额:$91.95万
-
财政年份:2008
-
负责人:Robert Walter Buckheit
-
依托单位:
Long Acting Acceptable Microbicides: Novel Delivery, Activity and Pharmacodynamic
-
批准号:7910678
-
项目类别:
-
资助金额:$157.83万
-
财政年份:2008
-
负责人:Robert Walter Buckheit
-
依托单位:
Administrative Core
-
批准号:7418072
-
项目类别:
-
资助金额:$4.87万
-
财政年份:2008
-
负责人:Robert Walter Buckheit
-
依托单位:
海外基金